Genetics of susceptibility to human infectious disease

Nature Reviews Genetics

Volumn 2, Issue 12, 2001, Pages 967-977

  Cooke, Graham S ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

COMMUNICABLE DISEASE; EVOLUTION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; HUMAN; REVIEW;

COMMUNICABLE DISEASES; EVOLUTION; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMAN; LINKAGE (GENETICS);

EID: 0035653671     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/35103577     Document Type: Review

References (123)

1. James, S. P., Nicol, W. D. & Shute, P. G. A study of malignant tertian malaria. Proc. R. Soc. Med. 25, 1153 (1932).
2. Modiano, D. et al. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc. Natl Acad. Sci. USA 93, 13206-13211 (1996). Study of three West African ethnic groups with similar exposure to malaria. It provides evidence that one group, the Fulani, might have genetic factors that enhance their immunity to malaria.
3. Stead, W. W., Senner, J. W. Reddick, W. T. & Lofgren, J. P. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N. Engl. J. Med. 322, 422-427 (1990).
4. Sorensen, T. I., Nielsen, G. G., Andersen, P. K. & Teasdale, T. W. Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med. 318, 727-732 (1988).
5. Siddiqui, M. R. et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nature Genet. 27, 439-441 (2001). The first demonstration that a major disease locus can be mapped using genome-wide linkage analysis in a complex infectious disease.
6. Marquet, S. et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nature Genet. 14, 181-184 (1996).
7. McGuffin, P. & Huckle, P. Simulation of Mendelism revisited: the recessive gene for attending medical school. Am. J. Hum. Genet. 46, 994-999 (1990).
8. Haldane, J. B. S. Disease and evolution. Ric. Sci. (Suppl. A), 68-76 (1949).
9. Lederberg, J. J. B. S. Haldane (1949) on infectious disease and evolution. Genetics 153, 1-3 (1999).
10. Allison, A. C. Protection afforded by sickle-cell trait against subtertian malarial infection. Br. Med. J. 290-294 (1954).
11. Hill, A. et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 352, 595-600 (1991).
12. Pasvol, G., Weatherall, D. J. & Wilson, R. J. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 274, 701-703 (1978).
13. Weatherall, D. J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nature Rev. Genet. 2, 245-255 (2001).
14. Flint, J. et al. High frequencies of α-thalassaemia are the result of natural selection by malaria. Nature 321, 744-750 (1986).
15. Willcox, M. et al. A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and β-thalassaemia traits. Ann. Trop. Med. Parasitol. 77, 239-246 (1983).
16. Williams, T. N. et al. High incidence of malaria in α-thalassaemic children, Nature 383, 522-525 (1996). Illustrates the new insights that are being gained into malarial immunity through the study of monogenic traits.
17. Ruwende, C. et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376, 246-249 (1995).
18. Friedman, M. J. Oxidant damage mediates variant red cell resistance to malaria. Nature 280, 245-247 (1979).
19. Levine, M. M. et al. Genetic susceptibility to cholera. Ann. Hum. Biol. 6, 369-374 (1979).
20. Tournamille, C., Colin, Y., Cartron, J. P. & Le Van Kim, C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nature Genet. 10, 224-228 (1995).
21. Miller, L. H., Mason, S. J., Clyde, D. F. & McGinniss, M. H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype. FyFy. N. Engl. J. Med. 295, 302-304 (1976).
22. Bertranpetit, J. & Calafell, F. Genetic and geographical variability in cystic fibrosis: evolutionary considerations. Ciba Found. Symp. 197, 97-114 (1996). Extensive discussion of the evidence that the gene responsible for cystic fibrosis has been subject to natural selection.
23. Thompson, E. A. & Neel, J. V. Allelic disequilibrium and allele frequency distribution as a function of social and demographic history. Am. J. Hum. Genet. 60, 197-204 (1997).
24. Pier, G. B. et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271, 64-67 (1996).
25. Pier, G. B. et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393, 79-82 (1998).
26. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
27. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001). References 26 and 27 describe two different approaches that show that major susceptibility genes can be mapped through linkage analysis of complex disease.
28. Fischer, A. Primary immunodeficiency disease: an experimental model for molecular medicine. Lancet 357, 1863-1869 (2001).
29. Korthauer, U. et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-lgM. Nature 361, 539-541 (1993).
30. DiSanto, J. P., Bonnefoy, J. Y., Gauchat, J. F., Fischer, A. & de Saint Basile, G. CD40 ligand mutations in X-linked immunodeficiency with hyper-lgM. Nature 361, 541-543 (1993).
31. Newport, M. J. et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941-1949 (1996).
32. Jouanguy, E. et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genet. 21, 370-378 (1999).
33. Altare, F. et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J. Clin. Invest. 102, 2035-2040 (1998).
34. De Jong, R. et al. Severe mycobacterial and Salmonella infections in interteukin-12 receptor-deficient patients. Science 280, 1435-1438 (1998).
35. Campbell, S. J. The identification of genetic susceptibility factors for tuberculosis. Ph.D. thesis, University of Oxford, UK (2001).
36. Ting, L. M., Kim, A. C., Cattamanchi, A. & Ernst, J. D. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163, 3898-3906 (1999).
37. Dupuis, S. et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293, 300-303 (2001).
38. Murphy, P. M. Molecular mimicry and the generation of host defense protein diversity. Cell 72, 823-826 (1993).
39. Hughes, A. L. & Nei, M. Nucleotide substitution at major histocompatability complex class II loci: evidence for overdominant selection. Proc. Natl Acad. Sci. USA 86, 958-962 (1989).
40. Doherty, P. C. & Zinkernagel, R. M. The biological role of the major histocompatibility antigens. Lancet 1, 1406-1409 (1975).
41. Carrington, M. et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748-1752 (1999).
42. Thursz, M. R., Thomas, H. C., Greenwood, B. M. & Hill, A. V. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nature Genet. 17, 11-12 (1997).
43. Cardon, L. R. & Bell, J. I. Association study designs for complex diseases. Nature Rev. Genet. 2, 91-99 (2001). Extensive review of the design and interpretation of association studies in complex disease.
44. Hill, A. V. HIV and HLA: confusion or complexity? Nature Med. 2, 395-396 (1996).
45. Kaslow, R. A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405-411 (1996).
46. Sahmoud, T. et al. Progression to AIDS in French haemophiliacs: association with HLA-B35. Aids 7, 497-500 (1993).
47. Scorza Smeraldi, R. et al. HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet 2, 1187-1189 (1986).
48. Gao, X. et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344, 1668-1675 (2001).
49. Kelleher, A. D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375-386 (2001).
50. Brahmajothi, V. et al. Association of pulmonary tuberculosis and HLA in south India. Tubercle 72, 123-132 (1991).
51. Visentainer, J. E., Tsuneto, L. T., Serra, M. F., Peixoto, P. R. & Petzl-Erler, M. L. Association of leprosy with HLA-DR2 in a Southern Brazilian population. Braz. J. Med. Biol. Res. 30, 51-59 (1997).
52. Thursz, M. MHC and the viral hepatitides. Quart. J. Med. 94, 287-291 (2001).
53. Alric, L. et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 113, 1675-1681 (1997).
54. Jepson, A. et al. Quantfication of the relative contribution of major histocompatibility complex (MHC) and non-MHC genes to human immune responses to foreign antigens. Infect. Immun. 65, 872-876 (1997).
55. Jepson, A. et al. Genetic regulation of acquired immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa. Infect. Immun. 69, 3989-3994 (2001).
56. Davies, J. L. et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371, 130-136 (1994).
57. McGuire, W. et al. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J. Infect. Dis. 179, 287-290 (1999).
58. Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O. & Duff, G. W. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 94, 3195-3199 (1997).
59. Knight, J. C. et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nature Genet. 22, 145-150 (1999). Important evidence of the functional properties of the tumour necrosis factor promoter polymorphisms that are associated with severe malaria.
60. Aitman, T. J. et al. Malaria susceptibility and CD36 mutation. Nature 405, 1015-1016 (2000).
61. Pain, A. et al. A non-sense mutation in Cd36 gene is associated with protection from severe malaria. Lancet 357, 1502-1503 (2001). References 60 and 61 show the heterogeneity of data in genetic studies and how such data can inform research on particular candidate genes.
62. Fernandez-Reyes, D. et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum. Mol. Genet. 6, 1357-1360 (1997).
63. Bellamy, R., Kwiatkowski, D. & Hill, A. V. Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interteukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. Trans. R. Soc. Trop. Med. Hyg. 92, 312-316 (1998).
64. Vidal, S. M., Malo, D., Vogan, K., Skamene, E. & Gros, P. Natural resistance to infection with intracellular parasites: isolation of a candidate for BCG. Cell 73, 469-485 (1993).
65. Gruenheid, S. & Gros, P. Genetic susceptibility to intracellular infectons: Nramp1, macrophage function and divalent cations transport. Curr. Opin. Microbiol. 3, 43-48 (2000).
66. Bellamy, R. et al. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N. Engl. J. Med. 338, 640-644 (1998).
67. Cervino, A. C., Lakiss, S., Sow, O. & Hill, A. V. Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea-Conakry. Ann. Hum. Genet. 64, 507-512 (2000).
68. Gao, P. S. et al. Genetic variants of NRAMP1 and active tuberculosis in Japanese populations. International Tuberculosis Genetics Team. Clin. Genet. 58, 74-76 (2000).
69. Greenwood, C. M. et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am. J. Hum. Genet. 67, 405-416 (2000).
70. Shaw, M. A. et al. Evidence that genetic susceptibility to Mycobacterium tuberculosis in a Brazilian population is under oligogenic control: linkage study of the candidate genes NRAMP1 and TNFA. Tuber. Lung Dis. 78, 35-45 (1997).
71. Bellamy, R. et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc. Natl Acad. Sci. USA 97, 8005-8009 (2000).
72. Abel, L. et al. Susceptibility to leprosy is linked to the human NRAMP1 gene. J. Infect. Dis. 177, 133-145 (1998).
73. Meisner, S. J. et al. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in West Africans. Am. J. Trop. Med. Hyg. (in the press).
74. Rook, G. A. et al. Vitamin D3, γ interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57, 159-163 (1986).
75. Wilkinson, R. J. et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 355, 618-621 (2000).
76. Douglas, A. S., Strachan, D. P. & Maxwell, J. D. Seasonality of tuberculosis: the reverse of other respiratory diseases in the UK. Thorax 51, 944-946 (1996).
77. Roy, S. et al. Association of vitamin D receptor genotype with leprosy type. J. Infect. Dis. 179, 187-191 (1999).
78. Bellamy, R. et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 179, 721-724 (1999).
79. Thiel, S. et al. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. J. Immunol. 165, 878-887 (2000).
80. Madsen, H. O. et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 40, 37-44 (1994).
81. Summerfield, J. A. et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345, 885-889 (1995).
82. Summerfield, J. A., Sumiya, M., Levin, M. & Turner, M. W. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Br. Med. J. 314, 1229-1232 (1997).
83. Koch, A. et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. J. Am. Med. Assoc. 285, 1316-1321 (2001).
84. Bellamy, R. et al. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. Quart. J. Med. 91, 13-18 (1998).
85. Hibberd, M. L., Sumiya, M., Summerfield, J. A., Booy, R. & Levin, M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 353, 1049-1053 (1999).
86. Neth, O., Hann, I., Turner, M. W. & Klein, N. J. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358, 614-618 (2001).
87. Lin, H. J. et al. Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families. Lancet 336, 208-212 (1990).
88. Blumberg, B. S., Friedlander, J. S., Woodside, A., Sutnick, A. I. & London, W. T. Hepatitis and Australia antigen: autosomal recessive inheritance of susceptibility to infection in humans. Proc. Natl Acad. Sci. USA 62, 1108-1115 (1969).
89. Shin, H. D. et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl Acad. Sci. USA 97, 14467-14472 (2000).
90. Akdis, C. A. & Blaser, K. Mechanisms for interteukin-10 mediated immune suppression. Immunology 103, 131-136 (2001).
91. Edwards-Smith, C. J. et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon α. Hepatology 30, 526-530 (1999).
92. Yee, L. J. et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33, 708-712 (2001).
93. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Mutticenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856-1862 (1996).
94. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240-1243 (1996).
95. Benkirane, M., Jin, D. Y., Chun, R. F., Koup, R. A. & Jeang, K. T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5δ32. J. Biol. Chem. 272, 30603-30606 (1997).
96. Zimmerman, P. A. et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3, 23-36 (1997).
97. Kostrikis, L. G. et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J. Virol. 73, 10264-10271 (1999).
98. Martin, M. P. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907-1911 (1998).
99. Smith, M. W. et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277, 959-965 (1997).
100. Winkler, C. et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279, 389-393 (1998).
101. Mummidi, S. et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med. 4, 786-793 (1998).
102. Marquet, S., Abel, L., Hillaire, D. & Dessein, A. Full results of the genome-wide scan which localises a focus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Eur. J. Hum. Genet. 7, 88-97 (1999). A report of the first genome-wide screen that used affected sib-pair analysis to study infectious burden.
103. Chakravarti, M. R. & Vogel, F. A Twin Study on Leprosy Vol. 1 (Stutthart Thieme, 1973).
104. Frodsham, A. The genetics of susceptibility to chronic hepatitis B infection. Ph.D. thesis, University of Oxford, UK (2000).
105. Rihet, P. et al. Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am. J. Hum. Genet. 63, 498-505 (1998).
106. Marsh, D. G. et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 264, 1152-1156 (1994).
107. Walley, A. J., Wiltshire, S., Ellis, C. M. & Cookson, W. O. Linkage and allelic association of chromosome 5 cytokine cluster genetic markers with atopy and asthma associated traits. Genomics 72, 15-20 (2001).
108. Holloway, J. W. et al. Linkage analysis of the 5q31-33 candidate region for asthma in 240 UK families. Genes Immun. 2, 20-24 (2001).
109. Beyer, K. et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J. Invest. Dermatol. 115, 906-908 (2000).
110. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2, 675-680 (2001).
111. Gilbert, S. C. et al. Association of malaria parasite population structure, HLA. and immunological antagonism. Science 279, 1173-1177 (1998). Demonstration of the complex interaction between variation in the human immune system and parasite variation in malaria.
112. Janeway, C. A. Jr & Travers, P. (eds) in Immunobiology: the Immune System in Health and Disease, 2nd Edn, Sect. 4 (1996).
113. Good, M. F. Towards a blood-stage vaccine for malaria: are we following all the leads? Nature Rev. Immunol. 1, 117-125 (2001).
114. Smith, K. J. et al. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to Ml+C class II HLA-B53. Immunity 4, 215-228 (1996).
115. Diehl, K. & Von Verschuer, O. Der Erbeinfluss bei den Tuberkulose. Beitr Klin Kunsch 92, 275 (1936).
116. Kallmann, F. J. & Reisner, D. Twin studies on the significance of genetic factors in tuberculosis. Am. Rev. Respir. Dis. 47, 549 (1942).
117. Comstock, G. W. Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117, 621 (1978).
118. Herndon, C. N. & Jennings, R. G. A twin family study on susceptibiltiy to poliomyelitis. Am. J. Hum. Genet. 3, 17 (1951).
119. Lin, T. M. et al. Hepatitis B virus markers in Chinese twins. Anticancer Res. 9, 737-741 (1989).
120. Thursz, M. R. et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 332, 1065-1069 (1995).
121. Thursz, M., Yallop, R., Goldin, R., Trepo, C. & Thomas, H. C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354, 2119-2124 (1999).
122. Dunstan, S. J. et al. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J. Infect. Dis. 183, 261-268 (2001).
123. Almam, A. & Batchelor, J. R. HLA and hepatitis B infection. Lancet 344, 1194-1195 (1994).